Navigation Links
Changing cancer's environment to halt its spread

Boston, Mass.By studying the roles two proteins, thrombospondin-1 and prosaposin, play in discouraging cancer metastasis, a trans-Atlantic research team has identified a five-amino acid fragment of prosaposin that significantly reduces metastatic spread in mouse models of prostate, breast and lung cancer. The findings suggest that a prosaposin-based drug could potentially block metastasis in a variety of cancers.

The study team, led by Randolph Watnick, PhD, at Boston Children's Hospital, Vivek Mittal, PhD, at Weill Cornell Medical College and Lars Akslen, MD, PhD, at the University of Bergen, released their findings in the May issue of the journal Cancer Discovery.

The main cause of cancer mortality is not the primary tumor itself, but rather its spreadmetastasisto other locations in the body and subsequent organ failure. Previous studies by Watnick, a member of Boston Children's Vascular Biology Program, and others have shown that tumors capable of metastasis release proteins that help prepare new homes in distant organs for their metastatic progeny.

Watnick's lab has also previously shown that tumors that cannot metastasize release prosaposin. This protein activates expression of a second protein called thrombospondin-1, a potent anti-angiogenic factor, in tissues where metastatic tumor cells could potentially take root. Thrombospondin-1 makes these otherwise-permissive tissues resistant to metastasis.

"In the past, we've struggled to determine the source of thrombospondin-1 production," Watnick says. "We knew it was coming from the tumor microenvironment, normal cells adjacent to the sites of potential metastasis, but we could not tell if those cells were native to the microenvironment or had been recruited from the bone marrow."

Using mouse models of breast, prostate and lung cancer, Watnick and his colleagues confirmed through bone marrow transplant and gene knockout experiments that both metastatic and non-metastatic tumors induce cells from the bone marrowspecifically, monocytes expressing the Gr1 surface markerto migrate to the lungs. However, non-metastatic tumors then trigger these monocytes to produce thrombospondin-1 by releasing prosaposin.

"Others have shown that tumors recruit monocytes to future metastatic sites, which help to set up a permissive environment for tumor cells to metastasize, " Watnick notes. "Our results suggest that non-metastatic tumors do the same thing, but instead of creating a permissive environment, the monocytes create a refractory environment by producing thrombospondin-1."

Watnick thinks this finding creates a window of therapeutic opportunity. "If we can trigger monocytes recruited by pro-metastatic tumors to produce thrombospondin-1 like those recruited by non-metastatic tumors, we will be able to hijack the mechanism by which tumors create metastasis-permissive sites to close the door on those sites."

Thrombospondin-1 itself, however, is too large to serve as a drug, and studies using shortened versions of the protein have not been promising. Watnick and his collaborators instead are focusing on prosaposin. To find the smallest part of prosaposin capable of activating thrombospondin-1, the team took an 80-amino acid region of prosaposin and whittled it down bit by bit until they isolated a five amino-acid peptide that could trigger thrombospondin-1 production as strongly as the full-length protein.

When administered in mouse models of metastatic cancer, this peptide significantly reduced metastasis compared to scrambled versions of the peptide (with the same amino acids but in different sequence), but only in mice with monocytes capable of producing thrombospondin-1.

Strikingly, Watnick and his collaborators also found that prostate cancer patients whose tumors expressed higher levels of prosaposin had significantly greater overall survival than patients whose tumors expressed low levels of prosaposin. Thus, with additional work, Watnick believes the prosaposin peptide could be the foundation for a tumor- and location-agnostic method of treating or preventing metastasis in patients with advanced cancers.

"The size of this peptide makes it ideal for drug development," Watnick says. "It's about as large as tyrosine kinase inhibitors such as Gleevec or Iressa, and could potentially be formulated in multiple ways for different types of cancer. I could also foresee using a therapeutic agent like this peptide as an adjuvant therapy, for example just as we now use chemotherapy or hormonal therapy for breast cancer."

Boston Children's Technology and Innovation Development Office (TIDO) has filed patent applications on these peptides, peptide derivatives and their uses. A start-up company is in the works.


Contact: Keri Stedman
Boston Children's Hospital

Related medicine news :

1. Brain structure helps guide behavior by anticipating changing demands
2. Birds Songs Reflect Changing Weather Patterns: Study
3. Changing epidemiology of rare disease links sinus irrigation with contaminated tap water, 2 deaths
4. Guidelines developed for extremely premature infants at NCH proven to be life-changing
5. Does changing the price of medicine influence consumers perceived health risk?
6. Changing Poses LLC Brings Balance to Chiropractic Treatment Tables, Complimentary Lavender Spray Cleaner with All Wholesale Orders
7. Panel recommends changing name of common disorder in women
8. Atlanta Opthalmologist Interviewed About LASIK Surgery’s Life-Changing Effects
9. Avoiding Hospital Readmissions Boot Camp and Survive and Thrive in the Changing Health Care Environment - ABQAURP's 36th Annual Health Care Quality Conference
10. Changing shape makes chemotherapy drugs better at targeting cancer cells
11. New data show countries around the world grappling with changing health challenges
Post Your Comments:
(Date:10/13/2015)... Angeles, CA (PRWEB) , ... October 13, 2015 , ... ... To incentivize would-be customers, eMarketing Concepts began a $1 promotion – effectively offering all ... a resounding success, and within weeks the company was flooded with phone calls from ...
(Date:10/13/2015)... ... , ... The Bill Howe Family of Companies is an award winning HVAC ... remediation services. Family-owned and operated for 35 years, they have maintained value, ethics and ... two years in a row from the Union Tribune Reader’s Poll, a Healthiest Company ...
(Date:10/12/2015)... ... 2015 , ... Heroes in Recovery (HIR) is proud to ... Network’s Moments of Change conference in West Palm Beach, Florida. Rob Waggener, CEO ... Dauphinais who exemplify the ideals of the Heroes in Recovery movement. , Noah ...
(Date:10/12/2015)... , ... October 12, 2015 , ... Kevin Costello, winner of the “Check-In and Win ... embarks today for his dream vacation to Hawaii. , “I didn’t believe I could win ... says. “This contest encouraged me to get to the gym and invest in my own ...
(Date:10/12/2015)... ... 12, 2015 , ... The American Society of Clinical Hypnosis ... education and clinical training in a health care discipline. , Many practitioners ... as: losing weight, managing pain, or stopping smoking, etc. Frequently, extravagant statements and ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... Therapy Catapult to advance development of large scale ... immunotherapy. Under the agreement, the Cell Therapy Catapult ... to support advanced clinical trials and eventual commercialization ... --> The Cell Therapy Catapult is a ...
(Date:10/12/2015)... WASHINGTON , Oct. 12, 2015  Former White House ... Press Secretary for the House Narcotics Committee, Robert Weiner ... "Rewriting Drug Policy." The two emphasize that this is now ... Clinton to Jeb Bush , Carly Fiorina ... Sordello cite the newest federal statistics, which they call "a ...
(Date:10/12/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic, and the Dental sectors of healthcare, announced today ... 2015, its guidance for the fourth quarter of 2015, ... Senior Secured Credit Facility. --> ...
Breaking Medicine Technology: